Relevium Medical
ActivePlatform injectable gel based therapeutic for osteoarthritis
About
Relevium Medical is developing an injectable gel for knee osteoarthritis. Approximately half the population will be diagnosed with this pain and progressive disease. Right now, patients have to undergo not only repeat injections to control their pain, but also have to take strong oral medications. Because the disease is progressive and only gets worse over time, many patients end up on highly addictive, high-dose opioids. To date, we have secured $3.7 million in non dilutive funding and completed preclinical testing. We demonstrated that our drug is safe, selectively blocks nerves that transmit pain, and provides pain relief that lasts four times as long. Insurance currently pays $770 per six-monthly treatment for knee osteoarthritis. With 5 million patients in the US, this represents a $7.7 Bn market opportunity. This platform biotherapeutic can also be used to treat other joints affects by osteoarthritis such as the hip and ankle, where the same problems exist in treatment care.
Founders · 1
Alison is CEO and Founder at Relevium Medical. Alison holds qualifications in Chemistry and Biochemical Engineering (M.Sc. & Ph.D.). She has worked for major multinational companies including ROCHE, Cook Medical and Boston Scientific; and completed the BioInnovate Fellowship in the prestigious Stanford BioDesign-affiliated program at NUI Galway, Ireland. She is the named inventor on over 20 patent publications and the winner of the Science Foundation of Ireland’s €1 million innovation prize.
Launch
ReleviumBio is developing a platform peptide gel-based therapy for Osteoarthritis
ReleviumBio presents PeptiFlex, a multimodal injectable gel-based therapy for knee osteoarthritis that combines a peptide (315y) with a polymer base to provide pain relief, joint lubrication, and cartilage protection, with preclinical data showing benefit up to 7 weeks and improved OARSI scores. They seek strategic partnerships or clinical trial collaborations.
From the original launch (Jul 2022) — may be outdated.
Formerly “Relevium”, “ReleviumBio”
Related startups
A therapeutics platform for curing inflammatory disorders
Longevity for the 99%.
